

CUSTOMER UPDATE

Thursday, 18 July 2019

Progress update on Mo-99 production

ANSTO has maintained production of Mo-99 for Australian customers over the past two weeks despite the temporary shutdown of the ANSTO Nuclear Medicine (ANM) facility.

Since ARPANSA granted ANSTO a limited license to recommence the manufacture of Mo-99 in the ANM facility, three production runs have been completed. These runs have progressed as planned and Mo-99 has been utilised to manufacture Gentech[®] generators. Due to the two week shutdown of ANM coinciding with a scheduled OPAL maintenance period of five days, the yields of Mo-99 that have been recovered have been lower than usual.

The lower yield has led to 3 sites receiving their delivery on Thursday 18 July, instead of on Sunday.

Production for the Gentech[®] generators scheduled for delivery on Thursday 18 July and Friday 19 July has been successful, with all deliveries on track.

It is anticipated that the Mo-99 yields from ANM will continue to increase over the coming days, which will allow Gentech[®] generator manufacture to return to normal from the week commencing 22 July.

ANSTO would like to take this opportunity to thank the Australian nuclear medicine community for their support. Should there be any change to the status of the supply of Mo-99 from ANM within the Australian market, ANSTO will advise our customers directly as well as continuing to keep the broader nuclear medicine community informed.

In the meantime, if you have any questions please contact us directly on the details below.

Contact ANSTO directly on 1800 251 572 for more information.

To keep up to date with news on ANSTO's health products and services, you can also join our new community group on LinkedIn:

ANSTO's Australian Nuclear Medicine network